German-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD).

French cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials of eryaspase in ALL and pancreatic cancer. 

As first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntington’s Disease.

Microsart ® @media Advanced System for Touch-free Membrane Transfer.

Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform.

Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well as Wellington Partners and new investor Amgen.

Late-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.

Scotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair.

Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.

The European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration!